The successful preclinical trials of Padcev for treating urothelial carcinoma have demonstrated the efficacy of targeting Nectin-4 in cancer drug development [42], concurrently propelling the advancement of Nectin-4 ADCs. This evidence concerns the gene NECTIN4 and urothelial carcinoma.